Table of Content

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer and Use of Chemotherapy Treatment
4.2.2 Increasing Research and Development Activities
4.3 Market Restraints
4.3.1 High Cost of Neutropenia Treatment
4.3.2 Stringent Rules and Regulations for Drug Approval
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION (Market Size by Value - in USD Million)
5.1 By Treatement
5.1.1 Antibiotic Therapy
5.1.2 Granulocute Colony-Stimulating Factor Therapy
5.1.3 Others
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Retail Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Rest of the World


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen, Inc.
6.1.2 Kyowa Hakko Kirin Co., Ltd.
6.1.3 Teva Pharmaceuticals Industries Ltd.
6.1.4 G1 Therapeutics
6.1.5 Spectrum Pharmaceuticals
6.1.6 Enzychem Lifesciences Corporation
6.1.7 Novartis AG
6.1.8 BeyondSpring Pharmaceuticals Inc
6.1.9 Coherus BioSciences, Inc.
6.1.10 Hanmi Pharmaceuticals Co. Ltd


7 MARKET OPPORTUNITIES AND FUTURE TRENDS